0001697751-19-000001.txt : 20190617 0001697751-19-000001.hdr.sgml : 20190617 20190617164102 ACCESSION NUMBER: 0001697751-19-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190617 DATE AS OF CHANGE: 20190617 EFFECTIVENESS DATE: 20190617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AsclepiX Therapeutics, Inc. CENTRAL INDEX KEY: 0001697751 IRS NUMBER: 832160334 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-324393 FILM NUMBER: 19901787 BUSINESS ADDRESS: STREET 1: 301 WEST 29TH STREET, SUITE 2004 CITY: BALTIMORE STATE: MD ZIP: 21211 BUSINESS PHONE: 610-212-1217 MAIL ADDRESS: STREET 1: 301 WEST 29TH STREET, SUITE 2004 CITY: BALTIMORE STATE: MD ZIP: 21211 FORMER COMPANY: FORMER CONFORMED NAME: AsclepiX Therapeutics, LLC DATE OF NAME CHANGE: 20170209 D/A 1 primary_doc.xml X0708 D/A LIVE 0001697751 AsclepiX Therapeutics, Inc. 301 WEST 29TH STREET, SUITE 2004 BALTIMORE MD MARYLAND 21211 610-212-1217 DELAWARE AsclepiX Therapeutics, LLC Corporation true Wendy Perrow 301 West 29th Street, Suite 2004 Baltimore MD MARYLAND 21211 Executive Officer Director Jordan J. Green 301 West 29th Street, Suite 2004 Baltimore MD MARYLAND 21211 Director Aleksander S. Popel, PhD 301 West 29th Street, Suite 2004 Baltimore MD MARYLAND 21211 Director Kevin Slawin, MD 301 West 29th Street, Suite 2004 Baltimore MD MARYLAND 21211 Director Joshua Barer 301 West 29th Street, Suite 2004 Baltimore MD MARYLAND 21211 Director Sapna Srivastava 301 West 29th Street, Suite 2004 Baltimore MD MARYLAND 21211 Director Steven Altschuler, MD 301 West 29th Street, Suite 2004 Baltimore MD MARYLAND 21211 Director Biotechnology Decline to Disclose 06b true 0001697751-18-000004 2018-10-12 false true true true false 0 Solebury Capital LLC 143299 None None 400 South River Road Suite 300 New Hope PA PENNSYLVANIA 18938 FL FLORIDA false 10000000 7735500 2264500 false 26 40000 true 0 575000 true false AsclepiX Therapeutics, Inc. Wendy Perrow Wendy Perrow Chief Executive Officer 2019-06-17